As a prelude to investigating the mechanism of regression of pressure overload-induced left ventricular (LV) hypertrophy (LVH), we studied the time course for the development and subsequent regression of LVH as well as accompanying alterations in cardiac function, histology, and gene expression. Mice were subjected to aortic banding for 4 or 8 wk to establish LVH, and regression was initiated by release of aortic banding for 6 wk. Progressive increase in LV mass and gradual chamber dilatation and dysfunction occurred after aortic banding. LVH was also associated with myocyte enlargement, interstitial fibrosis, and enhanced expression of atrial natriuretic peptide, collagen I, collagen III, and matrix metalloproteinase-2 but suppressed expression of ␣-myosin heavy chain and sarcoplasmic reticulum Ca 2ϩ -ATPase. Aortic debanding completely or partially reversed LVH, chamber dilatation and dysfunction, myocyte size, interstitial fibrosis, and gene expression pattern, each with a distinct time course. The extent of LVH regression was dependent on the duration of pressure overload, evidenced by the fact that restoration of LV structure and function was complete in animals subjected to 4 wk of aortic banding but incomplete in animals subjected to 8 wk of aortic banding. In conclusion, LVH regression comprises a variety of morphological, functional, and genetic components that show distinct time courses. A longer period of pressure overload is associated with a slower rate of LVH regression. aortic banding; cardiac function/remodeling; model MYOCARDIAL HYPERTROPHY OCCURS in response to a variety of biomechanical stimuli. Although left ventricular (LV) hypertrophy (LVH) in response to increased afterload can be viewed as a compensatory mechanism to maintain cardiac output and normalize wall stress, LVH in the long term is an independent risk factor for a range of adverse consequences, such as myocardial ischemia, systolic and diastolic dysfunction, arrhythmias, and cardiac mortality (4, 9, 18, 19). Therefore, prevention or regression of LVH is a major therapeutic target whether achieved by pharmacological, mechanical, surgical, or genetic means (11,21,27,35,38). There has been clinical evidence that regression of LVH reduces morbidity and mortality and improves prognosis (9, 32). For example, antihypertensive treatment and aortic valvular replacement reverse LV structural, functional, and electrophysiological abnormalities (12,26,28). Similar benefits have also been observed after drug treatment in different animal models (3,30). Although reversal of LVH occurs after control of etiological factors, some studies have revealed incomplete reversal of pathophysiological changes, such as interstitial fibrosis, ventricular remodeling and dysfunction, and aberrant electrophysiology (2, 3, 12). Although numerous clinical and experimental studies have investigated effects of antihypertensive drugs (1, 3), coronary structure and function (17, 29), and alteration in gene expression (7, 31, 36) during reversal of LVH, the pathophys...